{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:34:02Z","timestamp":1792197242090,"version":"4.4.0"},"reference-count":194,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2022,7,12]],"date-time":"2022-07-12T00:00:00Z","timestamp":1657584000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Life"],"abstract":"<jats:p>Modern antineoplastic therapy improves survival and quality of life in cancer patients, but its indisputable benefits are accompanied by multiple and major side effects, such as cardiovascular ones. Endothelial dysfunction, arterial spasm, intravascular thrombosis, and accelerated atherosclerosis affect the coronary arteries, leading to acute and chronic coronary syndromes that negatively interfere with the oncologic treatment. The cardiac toxicity of antineoplastic agents may be mitigated by using adequate prophylactic measures. In the absence of dedicated guidelines, our work provides the most comprehensive, systematized, structured, and up-to-date analyses of the available literature focusing on measures aiming to protect the coronary arteries from the toxicity of cancer therapy. Our work facilitates the implementation of these measures in daily practice. The ultimate goal is to offer clinicians the necessary data for a personalized therapeutic approach for cancer patients receiving evidence-based oncology treatments with potential cardiovascular toxicity.<\/jats:p>","DOI":"10.3390\/life12071034","type":"journal-article","created":{"date-parts":[[2022,7,12]],"date-time":"2022-07-12T03:50:36Z","timestamp":1657597836000},"page":"1034","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Myocardial Ischemia Related to Common Cancer Therapy\u2014Prevention Insights"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8942-1909","authenticated-orcid":false,"given":"Minerva Codruta","family":"Badescu","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, \u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 16 University Street, 700115 Iasi, Romania"},{"name":"III Internal Medicine Clinic, \u201cSt. Spiridon\u201d County Emergency Clinical Hospital, 1 Independence Boulevard, 700111 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oana Viola","family":"Badulescu","sequence":"additional","affiliation":[{"name":"Department of Pathophysiology, \u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 16 University Street, 700115 Iasi, Romania"},{"name":"Hematology Clinic, \u201cSt. Spiridon\u201d County Emergency Clinical Hospital, 1 Independence Boulevard, 700111 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dragos Viorel","family":"Scripcariu","sequence":"additional","affiliation":[{"name":"Surgery Department, \u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 16 University Street, 700115 Iasi, Romania"},{"name":"1st Surgical Oncology Unit, Regional Institute of Oncology, 2-4 General Henri Mathias Berthelot Street, 700483 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u0103cr\u0103mioara Ionela","family":"Butnariu","sequence":"additional","affiliation":[{"name":"Department of Mother and Child Medicine, \u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 700115 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris","family":"Bararu-Bojan","sequence":"additional","affiliation":[{"name":"Department of Pathophysiology, \u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 16 University Street, 700115 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Popescu","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, \u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 16 University Street, 700115 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Ciocoiu","sequence":"additional","affiliation":[{"name":"Department of Pathophysiology, \u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 16 University Street, 700115 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eusebiu Vlad","family":"Gorduza","sequence":"additional","affiliation":[{"name":"Department of Mother and Child Medicine, \u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 700115 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina Iuliana","family":"Costache","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, \u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 16 University Street, 700115 Iasi, Romania"},{"name":"Cardiology Clinic, \u201cSt. Spiridon\u201d County Emergency Clinical Hospital, 700111 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Rezus","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Physiotherapy, \u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 16 University Street, 700115 Iasi, Romania"},{"name":"I Rheumatology Clinic, Clinical Rehabilitation Hospital, 14 Pantelimon Halipa Street, 700661 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciprian","family":"Rezus","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, \u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 16 University Street, 700115 Iasi, Romania"},{"name":"III Internal Medicine Clinic, \u201cSt. Spiridon\u201d County Emergency Clinical Hospital, 1 Independence Boulevard, 700111 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,7,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3322\/caac.21254","article-title":"Cancer statistics, 2015","volume":"65","author":"Siegel","year":"2015","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S1470-2045(13)70546-1","article-title":"Cancer survival in Europe 1999\u20132007 by country and age: Results of EUROCARE--5-a population-based study","volume":"15","author":"Sant","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_3","first-page":"221","article-title":"Optimal management of coronary artery disease in cancer patients","volume":"5","author":"Han","year":"2019","journal-title":"Chronic Dis. Transl. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e005996","DOI":"10.1161\/JAHA.117.005996","article-title":"Statin Use and Risk of Vascular Events Among Cancer Patients After Radiotherapy to the Thorax, Head, and Neck","volume":"8","author":"Boulet","year":"2019","journal-title":"J. Am. Heart Assoc."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","article-title":"2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)","volume":"37","author":"Zamorano","year":"2016","journal-title":"Eur. Heart J."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e021686","DOI":"10.1161\/JAHA.121.021686","article-title":"Radiation-Induced Cardiovascular Disease: Review of an Underrecognized Pathology","volume":"10","author":"Eisenberg","year":"2021","journal-title":"J. Am. Heart Assoc."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1097\/HCO.0000000000000404","article-title":"Radiotherapy, chemotherapy and atherosclerosis","volume":"32","author":"Min","year":"2017","journal-title":"Curr. Opin. Cardiol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.jaccao.2021.07.008","article-title":"Coronary Artery Disease in Young Women After Radiation Therapy for Breast Cancer: The WECARE Study","volume":"3","author":"Carlson","year":"2021","journal-title":"JACC Cardio Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"4649","DOI":"10.1200\/JCO.2010.29.9362","article-title":"Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: A 20-year follow-up study","volume":"28","author":"Haugnes","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.3390\/cancers2031717","article-title":"5-FU metabolism in cancer and orally-administrable 5-FU drugs","volume":"2","author":"Miura","year":"2010","journal-title":"Cancers"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1758835918780140","DOI":"10.1177\/1758835918780140","article-title":"5-fluorouracil and cardiotoxicity: A review","volume":"10","author":"Sara","year":"2018","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1093\/annonc\/mdu055","article-title":"Effort myocardial ischemia during chemotherapy with 5-fluorouracil: An underestimated risk","volume":"25","author":"Lestuzzi","year":"2014","journal-title":"Ann. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1200\/JCO.1989.7.4.509","article-title":"Continuous ambulatory ECG monitoring during fluorouracil therapy: A prospective study","volume":"7","author":"Rezkalla","year":"1989","journal-title":"J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.ejca.2005.03.027","article-title":"The frequency and pattern of cardiotoxicity observed with capecitabine used in conjunction with oxaliplatin in patients treated for advanced colorectal cancer (CRC)","volume":"41","author":"Ng","year":"2005","journal-title":"Eur. J. Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Hilmi, M., Ederhy, S., Waintraub, X., Funck-Brentano, C., Cohen, A., Vozy, A., Lebrun-Vignes, B., Moslehi, J., Nguyen, L.S., and Salem, J.E. (2020). Cardiotoxicity Associated with Gemcitabine: Literature Review and a Pharmacovigilance Study. Pharmaceuticals, 13.","DOI":"10.3390\/ph13100325"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s11864-020-0719-1","article-title":"Cardiotoxicities of 5-Fluorouracil and Other Fluoropyrimidines","volume":"21","author":"Shiga","year":"2020","journal-title":"Curr. Treat Options Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1517\/14740330902733961","article-title":"Fluoropyrimidine-associated cardiotoxicity: Revisited","volume":"8","author":"Saif","year":"2009","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_18","first-page":"3028","article-title":"In vitro evidence that myocardial ischemia resulting from 5-fluorouracil chemotherapy is due to protein kinase C-mediated vasoconstriction of vascular smooth muscle","volume":"53","author":"Mosseri","year":"1993","journal-title":"Cancer Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1093\/oxfordjournals.annonc.a058084","article-title":"Very high endothelin plasma levels in patients with 5-FU cardiotoxicity","volume":"3","author":"Thyss","year":"1992","journal-title":"Ann. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1159\/000163051","article-title":"Gemcitabine-induced acute coronary syndrome: A case report","volume":"18","author":"Ozturk","year":"2009","journal-title":"Med. Princ. Pract."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1177\/107327480401100107","article-title":"5-fluorouracil-induced coronary vasospasm","volume":"11","author":"Shoemaker","year":"2004","journal-title":"Cancer Control"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s11912-016-0521-1","article-title":"Fluoropyrimidine-Induced Cardiotoxicity: Manifestations, Mechanisms, and Management","volume":"18","author":"Layoun","year":"2016","journal-title":"Curr. Oncol. Rep."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Polk, A., Vistisen, K., Vaage-Nilsen, M., and Nielsen, D.L. (2014). A systematic review of the pathophysiology of 5-fluorouracil-induced cardiotoxicity. BMC Pharmacol. Toxicol., 15.","DOI":"10.1186\/2050-6511-15-47"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s00280-005-0178-1","article-title":"Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil or capecitabine","volume":"58","author":"Jensen","year":"2006","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/sca.4950230101","article-title":"Antithrombotic treatment in protection against thrombogenic effects of 5-fluorouracil on vascular endothelium: A scanning microscopy evaluation","volume":"23","author":"Kinhult","year":"2001","journal-title":"Scanning"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1080\/02841860310004409","article-title":"Effects of probucol on endothelial damage by 5-fluorouracil","volume":"42","author":"Kinhult","year":"2003","journal-title":"Acta Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Focaccetti, C., Bruno, A., Magnani, E., Bartolini, D., Principi, E., Dallaglio, K., Bucci, E.O., Finzi, G., Sessa, F., and Noonan, D.M. (2015). Effects of 5-fluorouracil on morphology, cell cycle, proliferation, apoptosis, autophagy and ROS production in endothelial cells and cardiomyocytes. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0115686"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3390\/molecules14010053","article-title":"Decreased oxygen transfer capacity of erythrocytes as a cause of 5-fluorouracil related ischemia","volume":"14","author":"Spasojevic","year":"2008","journal-title":"Molecules"},{"key":"ref_29","first-page":"71","article-title":"Capecitabine-induced coronary artery vasospasm in a patient who previously experienced a similar episode with fluorouracil therapy","volume":"44","author":"Karakulak","year":"2016","journal-title":"Turk Kardiyol Dern Ars"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.hlc.2006.03.010","article-title":"Acute coronary syndrome induced by capecitabine therapy","volume":"15","author":"Wijesinghe","year":"2006","journal-title":"Heart Lung Circ."},{"key":"ref_31","first-page":"13","article-title":"5-FU induced cardiotoxicity: Case series and review of the literature","volume":"5","author":"Yuan","year":"2019","journal-title":"Cardiooncology"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1177\/000331970605700314","article-title":"Gemcitabine and acute myocardial infarction--a case report","volume":"57","author":"Bdair","year":"2006","journal-title":"Angiology"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1046\/j.1365-2141.2001.02795.x","article-title":"Gemcitabine as a single agent in the treatment of relapsed or refractory low-grade non-Hodgkin\u2019s lymphoma","volume":"113","author":"Dumontet","year":"2001","journal-title":"Br. J. Haematol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1177\/000331979905001208","article-title":"Acute myocardial infarction following gemcitabine therapy\u2014A case report","volume":"50","author":"Kalapura","year":"1999","journal-title":"Angiology"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"722","DOI":"10.2459\/JCM.0b013e32832bb9b1","article-title":"Capecitabine-induced cardiotoxicity: When to suspect? How to manage? A case report","volume":"10","author":"Farina","year":"2009","journal-title":"J. Cardiovasc. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/BF03086265","article-title":"Capecitabine-induced cardiotoxicity mimicking myocardial infarction","volume":"17","author":"Senturk","year":"2009","journal-title":"Neth. Heart J."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.3109\/02841869009091790","article-title":"Failure of preventing 5-fluorouracil cardiotoxicity by prophylactic treatment with verapamil","volume":"29","author":"Eskilsson","year":"1990","journal-title":"Acta Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.amjcard.2012.07.026","article-title":"Capecitabine-induced chest pain relieved by diltiazem","volume":"110","author":"Ambrosy","year":"2012","journal-title":"Am. J. Cardiol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/S0002-9343(88)80268-7","article-title":"Prophylaxis of 5-fluorouracil-induced coronary vasospasm with calcium channel blockers","volume":"85","author":"Oleksowicz","year":"1988","journal-title":"Am. J. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.ctrv.2010.11.001","article-title":"Cardiovascular effects of systemic cancer treatment","volume":"37","author":"Senkus","year":"2011","journal-title":"Cancer Treat Rev."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"970","DOI":"10.21037\/jgo.2017.09.07","article-title":"Fluoropyrimidine-induced cardiac toxicity: Challenging the current paradigm","volume":"8","author":"Clasen","year":"2017","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1093\/annonc\/mdx360","article-title":"Long-term toxicity of cisplatin in germ-cell tumor survivors","volume":"28","author":"Chovanec","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1200\/JCO.2000.18.10.2169","article-title":"Thromboembolic events during chemotherapy for germ cell cancer: A cohort study and review of the literature","volume":"18","author":"Weijl","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.ctrv.2011.09.002","article-title":"Endothelial vascular toxicity from chemotherapeutic agents: Preclinical evidence and clinical implications","volume":"38","author":"Soultati","year":"2012","journal-title":"Cancer Treat Rev."},{"key":"ref_45","first-page":"OD05","article-title":"Cisplatin Induced Acute Myocardial Infarction and Dyslipidemia","volume":"11","author":"Hanchate","year":"2017","journal-title":"J. Clin. Diagn. Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3892\/mco.2016.1107","article-title":"Paclitaxel and platinum-based chemotherapy results in transient dyslipidemia in cancer patients","volume":"6","author":"Wang","year":"2017","journal-title":"Mol. Clin. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1200\/JCO.2000.18.8.1725","article-title":"Cardiovascular morbidity in long-term survivors of metastatic testicular cancer","volume":"18","author":"Meinardi","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1093\/annonc\/mdl372","article-title":"Components of the metabolic syndrome in long-term survivors of testicular cancer","volume":"18","author":"Haugnes","year":"2007","journal-title":"Ann. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"3466","DOI":"10.1200\/JCO.2011.35.5669","article-title":"High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: A large retrospective analysis","volume":"29","author":"Moore","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e241","DOI":"10.2459\/JCM.0000000000000444","article-title":"A rare case of large intracoronary thrombosis in advanced breast cancer patient treated with epirubicin and cisplatin","volume":"17","author":"Centola","year":"2016","journal-title":"J. Cardiovasc. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"A17234","DOI":"10.1161\/circ.144.suppl_2.17234","article-title":"Cisplatin induced coronary artery atherosclerosis leading to ST-elevation myocardial infarction: A case report","volume":"144","author":"Khalid","year":"2021","journal-title":"Circulation"},{"key":"ref_52","first-page":"E18","article-title":"Multiple coronary thrombi with cisplatin","volume":"26","author":"Karabay","year":"2014","journal-title":"J. Invasive Cardiol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"583","DOI":"10.3109\/07357909009018924","article-title":"Acute coronary events following cisplatin-based chemotherapy","volume":"8","author":"Berliner","year":"1990","journal-title":"Cancer Investig."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"4040","DOI":"10.12998\/wjcc.v9.i16.4040","article-title":"Acute inferior myocardial infarction in a young man with testicular seminoma: A case report","volume":"9","author":"Bataila","year":"2021","journal-title":"World J. Clin. Cases"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"436","DOI":"10.2169\/internalmedicine.38.436","article-title":"Vasospastic angina likely related to cisplatin-containing chemotherapy and thoracic irradiation for lung cancer","volume":"38","author":"Fukuda","year":"1999","journal-title":"Intern. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"983","DOI":"10.4103\/0973-1482.157320","article-title":"A rare case of cisplatin-induced acute myocardial infarction in a patient receiving chemoradiation for lung cancer","volume":"11","author":"Rao","year":"2015","journal-title":"J. Cancer Res. Ther."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.amsu.2019.07.018","article-title":"Spontaneous coronary artery dissection during cisplatin and capecitabine therapy","volume":"45","author":"Somov","year":"2019","journal-title":"Ann. Med. Surg."},{"key":"ref_58","first-page":"54","article-title":"Myocardial infarction in a young patient with seminoma during chemotherapy with cisplatinum, etoposide, and bleomycin","volume":"52","author":"Brinkmann","year":"2021","journal-title":"Aktuelle Urol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"537","DOI":"10.6004\/jnccn.2012.0051","article-title":"Late cardiovascular toxicity following chemotherapy for germ cell tumors","volume":"10","author":"Feldman","year":"2012","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1093\/ehjci\/jeaa289","article-title":"The cardiac impact of cisplatin-based chemotherapy in survivors of testicular cancer: A 30-year follow-up","volume":"22","author":"Bjerring","year":"2021","journal-title":"Eur. Heart J. Cardiovasc. Imaging"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.cjca.2015.12.023","article-title":"Vascular Complications of Cancer Chemotherapy","volume":"32","author":"Cameron","year":"2016","journal-title":"Can. J. Cardiol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"9130","DOI":"10.1200\/JCO.2005.01.4092","article-title":"Acute chemotherapy-induced cardiovascular changes in patients with testicular cancer","volume":"23","author":"Nuver","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/ccr3.2601","article-title":"Coronary vasospasm induced by cisplatin for seminoma","volume":"8","author":"Sasaki","year":"2020","journal-title":"Clin. Case Rep."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.toxrep.2015.07.009","article-title":"The effects of N-acetylcysteine on cisplatin-induced cardiotoxicity on isolated rat hearts after short-term global ischemia","volume":"2","author":"Rosic","year":"2015","journal-title":"Toxicol. Rep."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.ejphar.2010.09.085","article-title":"Cisplatin-induced cardiotoxicity: Mechanisms and cardioprotective strategies","volume":"650","author":"Moustafa","year":"2011","journal-title":"Eur. J. Pharmacol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"4242","DOI":"10.1093\/eurheartj\/ehz425","article-title":"Corrigendum to: 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes","volume":"41","author":"Knuuti","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"767","DOI":"10.4070\/kcj.2018.0251","article-title":"Coronary Artery Vasospasm","volume":"48","author":"Song","year":"2018","journal-title":"Korean Circ. J."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"351","DOI":"10.3109\/0284186X.2013.819116","article-title":"Abdominal visceral and subcutaneous fat increase, insulin resistance and hyperlipidemia in testicular cancer patients treated with cisplatin-based chemotherapy","volume":"53","author":"Willemse","year":"2014","journal-title":"Acta Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1093\/annonc\/mds527","article-title":"Early development of the metabolic syndrome after chemotherapy for testicular cancer","volume":"24","author":"Altena","year":"2013","journal-title":"Ann. Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.critrevonc.2016.10.011","article-title":"Cancer treatment induced metabolic syndrome: Improving outcome with lifestyle","volume":"108","author":"Westerink","year":"2016","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"592","DOI":"10.3109\/0284186X.2014.995776","article-title":"Treatment-related cardiovascular late effects and exercise training countermeasures in testicular germ cell cancer survivorship","volume":"54","author":"Christensen","year":"2015","journal-title":"Acta Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"507","DOI":"10.3322\/caac.21411","article-title":"Treatment of renal cell carcinoma: Current status and future directions","volume":"67","author":"Barata","year":"2017","journal-title":"CA Cancer J. Clin."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"12113","DOI":"10.2147\/OTT.S276150","article-title":"Anti-Angiogenic Therapy in the Treatment of Non-Small Cell Lung Cancer","volume":"13","author":"Tian","year":"2020","journal-title":"Onco Targets Ther."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Mossenta, M., Busato, D., Baboci, L., Cintio, F.D., Toffoli, G., and Bo, M.D. (2019). New Insight into Therapies Targeting Angiogenesis in Hepatocellular Carcinoma. Cancers, 11.","DOI":"10.3390\/cancers11081086"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"5025","DOI":"10.21873\/anticanres.11071","article-title":"Antiangiogenic therapy in pancreatic neuroendocrine tumors","volume":"36","author":"Capozzi","year":"2016","journal-title":"Anticancer Res."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"417","DOI":"10.3892\/ol.2021.12678","article-title":"Improved understanding of gastrointestinal stromal tumors biology as a step for developing new diagnostic and therapeutic schemes","volume":"21","author":"Fudalej","year":"2021","journal-title":"Oncol. Lett."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ejca.2018.10.009","article-title":"Efficacy of bevacizumab in first-line treatment of metastatic colorectal cancer: A systematic review and meta-analysis","volume":"106","author":"Baraniskin","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"838133","DOI":"10.3389\/fphar.2022.838133","article-title":"Targeting Angiogenesis in Breast Cancer: Current Evidence and Future Perspectives of Novel Anti-Angiogenic Approaches","volume":"13","author":"Ayoub","year":"2022","journal-title":"Front. Pharmacol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.jash.2018.03.008","article-title":"Vascular toxicities with VEGF inhibitor therapies-focus on hypertension and arterial thrombotic events","volume":"12","author":"Touyz","year":"2018","journal-title":"J. Am. Soc. Hypertens."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/ncponc0403","article-title":"Lessons from phase III clinical trials on anti-VEGF therapy for cancer","volume":"3","author":"Jain","year":"2006","journal-title":"Nat. Clin. Pract. Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Chen, X.L., Lei, Y.H., Liu, C.F., Yang, Q.F., Zuo, P.Y., Liu, C.Y., Chen, C.Z., and Liu, Y.W. (2013). Angiogenesis inhibitor bevacizumab increases the risk of ischemic heart disease associated with chemotherapy: A meta-analysis. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0066721"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"H1395","DOI":"10.1152\/ajpheart.01277.2005","article-title":"Mechanisms of endothelial response to oxidative aggression: Protective role of autologous VEGF and induction of VEGFR2 by H2O2","volume":"291","author":"Deudero","year":"2006","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3109\/02841860903524396","article-title":"Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: A meta-analysis of randomized controlled trials","volume":"49","author":"Ranpura","year":"2010","journal-title":"Acta Oncol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1093\/jnci\/djm086","article-title":"Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab","volume":"99","author":"Scappaticci","year":"2007","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"e006278","DOI":"10.1161\/JAHA.117.006278","article-title":"Cardiovascular Adverse Events in Patients With Cancer Treated With Bevacizumab: A Meta-Analysis of More Than 20 000 Patients","volume":"6","author":"Totzeck","year":"2017","journal-title":"J. Am. Heart Assoc."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1200\/JCO.2009.27.2757","article-title":"Risk of arterial thromboembolic events with sunitinib and sorafenib: A systematic review and meta-analysis of clinical trials","volume":"28","author":"Choueiri","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","article-title":"Sorafenib in advanced clear-cell renal-cell carcinoma","volume":"356","author":"Escudier","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1186\/s13256-016-0961-0","article-title":"Long-term response of over ten years with sorafenib monotherapy in metastatic renal cell carcinoma: A case report","volume":"10","author":"Ueda","year":"2016","journal-title":"J. Med. Case Rep."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"3695","DOI":"10.2147\/OTT.S103735","article-title":"Risk of venous and arterial thromboembolic events associated with anti-VEGF agents in advanced non-small-cell lung cancer: A meta-analysis and systematic review","volume":"9","author":"Zhang","year":"2016","journal-title":"Onco Targets Ther."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1093\/annonc\/mdq702","article-title":"Risk of arterial thromboembolic events in patients with advanced colorectal cancer receiving bevacizumab","volume":"22","author":"Tebbutt","year":"2011","journal-title":"Ann. Oncol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1161\/CIRCULATIONAHA.115.018347","article-title":"Vascular Toxicities of Cancer Therapies: The Old and the New--An Evolving Avenue","volume":"133","author":"Herrmann","year":"2016","journal-title":"Circulation"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"5204","DOI":"10.1200\/JCO.2007.15.6331","article-title":"Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma","volume":"26","author":"Schmidinger","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1053\/j.ajkd.2006.11.039","article-title":"Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: Systematic review and meta-analysis","volume":"49","author":"Zhu","year":"2007","journal-title":"Am. J. Kidney Dis."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/02841860802314720","article-title":"Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: Systematic review and meta-analysis","volume":"48","author":"Zhu","year":"2009","journal-title":"Acta Oncol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1470-2045(08)70003-2","article-title":"Incidence and risk of hypertension with sorafenib in patients with cancer: A systematic review and meta-analysis","volume":"9","author":"Wu","year":"2008","journal-title":"Lancet Oncol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1093\/eurheartj\/ehn384","article-title":"Bevacizumab treatment for cancer patients with cardiovascular disease: A double edged sword?","volume":"29","author":"Pereg","year":"2008","journal-title":"Eur. Heart J."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/S1470-2045(09)70222-0","article-title":"Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: A systematic review and meta-analysis of clinical trials","volume":"10","author":"Je","year":"2009","journal-title":"Lancet Oncol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1002\/ejhf.1920","article-title":"Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: A position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society","volume":"22","author":"Lyon","year":"2020","journal-title":"Eur. J. Heart Fail."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.cjca.2014.02.011","article-title":"Hypertension due to antiangiogenic cancer therapy with vascular endothelial growth factor inhibitors: Understanding and managing a new syndrome","volume":"30","author":"Small","year":"2014","journal-title":"Can. J. Cardiol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/ajh\/hpt201","article-title":"Vascular endothelial growth factor inhibitor-induced hypertension: From pathophysiology to prevention and treatment based on long-acting nitric oxide donors","volume":"27","author":"Kruzliak","year":"2014","journal-title":"Am. J. Hypertens."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1067\/mhj.2000.110093","article-title":"Carvedilol improves endothelium-dependent dilatation in patients with coronary artery disease","volume":"140","author":"Matsuda","year":"2000","journal-title":"Am. Heart J."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.semnephrol.2010.09.007","article-title":"Hypertension induced by vascular endothelial growth factor signaling pathway inhibition: Mechanisms and potential use as a biomarker","volume":"30","author":"Robinson","year":"2010","journal-title":"Semin. Nephrol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","article-title":"A Randomized Trial of Intensive versus Standard Blood-Pressure Control","volume":"373","author":"Group","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1161\/01.RES.0000014081.30867.F8","article-title":"Double-edged role of statins in angiogenesis signaling","volume":"90","author":"Urbich","year":"2002","journal-title":"Circ. Res."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC Guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"NP1","DOI":"10.1177\/2047487316653709","article-title":"2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts): Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR)","volume":"23","author":"Piepoli","year":"2016","journal-title":"Eur. J. Prev. Cardiol."},{"key":"ref_107","first-page":"136","article-title":"Bevacizumab\u2014cardiovascular side effects in daily practice","volume":"12","author":"Lewandowski","year":"2016","journal-title":"Oncol. Clin. Pract."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1001\/jamainternmed.2015.1180","article-title":"Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk","volume":"175","author":"Schaapveld","year":"2015","journal-title":"JAMA Intern. Med."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"e005633","DOI":"10.1161\/JAHA.117.005633","article-title":"Long-Term Cardiovascular Risk After Radiotherapy in Women With Breast Cancer","volume":"6","author":"Cheng","year":"2017","journal-title":"J. Am. Heart Assoc."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/0006-2952(75)90415-3","article-title":"Aggregation of blood platelets by adrenaline and its uptake","volume":"24","author":"Barthel","year":"1975","journal-title":"Biochem. Pharmacol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1093\/jnci\/djk029","article-title":"Myocardial infarction mortality risk after treatment for Hodgkin disease: A collaborative British cohort study","volume":"99","author":"Swerdlow","year":"2007","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1182\/blood-2006-07-034405","article-title":"Late cardiotoxicity after treatment for Hodgkin lymphoma","volume":"109","author":"Aleman","year":"2007","journal-title":"Blood"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa1209825","article-title":"Risk of ischemic heart disease in women after radiotherapy for breast cancer","volume":"368","author":"Darby","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1001\/jama.290.21.2831","article-title":"Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of hodgkin lymphoma treated with radiation therapy","volume":"290","author":"Hull","year":"2003","journal-title":"JAMA"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s11936-013-0259-0","article-title":"Radiation-induced cardiovascular disease","volume":"15","author":"Mousavi","year":"2013","journal-title":"Curr. Treat Options Cardiovasc. Med."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1016\/j.jacc.2013.01.090","article-title":"Cardiac complications of thoracic irradiation","volume":"61","author":"Jaworski","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1016\/j.ijrobp.2007.05.034","article-title":"Cardiac exposures in breast cancer radiotherapy: 1950s-1990s","volume":"69","author":"Taylor","year":"2007","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"4100","DOI":"10.1200\/JCO.2005.05.1037","article-title":"Late cardiac mortality and morbidity in early-stage breast cancer patients after breast-conservation treatment","volume":"24","author":"Harris","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.jacc.2010.08.638","article-title":"Long-term cardiovascular mortality after radiotherapy for breast cancer","volume":"57","author":"Bouillon","year":"2011","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.radonc.2011.01.004","article-title":"Dosimetric comparison of left-sided whole breast irradiation with 3DCRT, forward-planned IMRT, inverse-planned IMRT, helical tomotherapy, and topotherapy","volume":"100","author":"Schubert","year":"2011","journal-title":"Radiother. Oncol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1016\/j.ijrobp.2010.04.072","article-title":"Evaluation of four techniques using intensity-modulated radiation therapy for comprehensive locoregional irradiation of breast cancer","volume":"78","author":"Jagsi","year":"2010","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1053\/j.seminoncol.2013.01.007","article-title":"Cardiac complications after radical radiotherapy","volume":"40","author":"Martinou","year":"2013","journal-title":"Semin. Oncol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1182\/blood-2010-01-263764","article-title":"A population-based study of cardiac morbidity among Hodgkin lymphoma patients with preexisting heart disease","volume":"116","author":"Myrehaug","year":"2010","journal-title":"Blood"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"652761","DOI":"10.3389\/fcvm.2021.652761","article-title":"Radiation-Induced Vascular Disease-A State-of-the-Art Review","volume":"8","author":"Yang","year":"2021","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1200\/JCO.2008.20.2267","article-title":"Role of cancer treatment in long-term overall and cardiovascular mortality after childhood cancer","volume":"28","author":"Tukenova","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"32","DOI":"10.2214\/AJR.07.3112","article-title":"Coronary artery disease after radiation therapy for Hodgkin\u2019s lymphoma: Coronary CT angiography findings and calcium scores in nine asymptomatic patients","volume":"191","author":"Rademaker","year":"2008","journal-title":"AJR Am. J. Roentgenol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1200\/JCO.2009.25.2627","article-title":"Evaluation of coronary artery disease by computed tomography angiography in patients treated for childhood Hodgkin\u2019s lymphoma","volume":"28","author":"Kupeli","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1182\/blood-2010-06-291328","article-title":"Clinically significant cardiac disease in patients with Hodgkin lymphoma treated with mediastinal irradiation","volume":"117","author":"Galper","year":"2011","journal-title":"Blood"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1378\/chest.83.6.875","article-title":"Radiation-related chronic heart disease","volume":"83","author":"Totterman","year":"1983","journal-title":"Chest"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"649","DOI":"10.2353\/ajpath.2006.050409","article-title":"Ionizing radiation accelerates the development of atherosclerotic lesions in ApoE-\/- mice and predisposes to an inflammatory plaque phenotype prone to hemorrhage","volume":"168","author":"Stewart","year":"2006","journal-title":"Am. J. Pathol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1136\/heartjnl-2017-312123","article-title":"How to prevent and manage radiation-induced coronary artery disease","volume":"104","author":"Cuomo","year":"2018","journal-title":"Heart"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1136\/hrt.69.6.496","article-title":"Severe coronary artery disease after radiation therapy of the chest and mediastinum: Clinical presentation and treatment","volume":"69","author":"Orzan","year":"1993","journal-title":"Br. Heart J."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"317659","DOI":"10.4061\/2011\/317659","article-title":"Radiation-induced heart disease: A clinical update","volume":"2011","author":"Yusuf","year":"2011","journal-title":"Cardiol. Res. Pract."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3389\/fonc.2015.00039","article-title":"Radiation-induced heart disease: Pathologic abnormalities and putative mechanisms","volume":"5","author":"Taunk","year":"2015","journal-title":"Front. Oncol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"e014668","DOI":"10.1161\/JAHA.119.014668","article-title":"Exploratory Review of the Role of Statins, Colchicine, and Aspirin for the Prevention of Radiation-Associated Cardiovascular Disease and Mortality","volume":"9","author":"Silver","year":"2020","journal-title":"J. Am. Heart Assoc."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1080\/09553002.2021.1956007","article-title":"The cardiac toxicity of radiotherapy - a review of characteristics, mechanisms, diagnosis, and prevention","volume":"97","author":"Wei","year":"2021","journal-title":"Int. J. Radiat. Biol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.ijrobp.2009.09.064","article-title":"Radiation-related heart disease: Current knowledge and future prospects","volume":"76","author":"Darby","year":"2010","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_138","first-page":"1800","article-title":"Dosimetric comparison between three- and four-dimensional computerised tomography radiotherapy for breast cancer","volume":"18","author":"Yan","year":"2019","journal-title":"Oncol. Lett."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1159\/000453607","article-title":"Is the Deep Inspiration Breath-Hold Technique Superior to the Free Breathing Technique in Cardiac and Lung Sparing while Treating both Left-Sided Post-Mastectomy Chest Wall and Supraclavicular Regions?","volume":"10","author":"Darapu","year":"2017","journal-title":"Case Rep. Oncol."},{"key":"ref_140","doi-asserted-by":"crossref","unstructured":"Dell\u2019Oro, M., Giles, E., Sharkey, A., Borg, M., Connell, C., and Bezak, E. (2019). A Retrospective Dosimetric Study of Radiotherapy Patients with Left-Sided Breast Cancer; Patient Selection Criteria for Deep Inspiration Breath Hold Technique. Cancers, 11.","DOI":"10.3390\/cancers11020259"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1200\/JCO.2016.70.5400","article-title":"Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline","volume":"35","author":"Armenian","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s12282-019-01023-9","article-title":"Meta-analysis of deep inspiration breath hold (DIBH) versus free breathing (FB) in postoperative radiotherapy for left-side breast cancer","volume":"27","author":"Lai","year":"2020","journal-title":"Breast Cancer"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"333","DOI":"10.3109\/0284186X.2011.618510","article-title":"Radiation during deep inspiration allows loco-regional treatment of left breast and axillary-, supraclavicular- and internal mammary lymph nodes without compromising target coverage or dose restrictions to organs at risk","volume":"51","author":"Hjelstuen","year":"2012","journal-title":"Acta Oncol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3109\/0284186X.2010.512923","article-title":"Cardiac and pulmonary dose reduction for tangentially irradiated breast cancer, utilizing deep inspiration breath-hold with audio-visual guidance, without compromising target coverage","volume":"50","author":"Vikstrom","year":"2011","journal-title":"Acta Oncol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"105","DOI":"10.4048\/jbc.2012.15.1.105","article-title":"Dose-Volume Analysis of Lung and Heart according to Respiration in Breast Cancer Patients Treated with Breast Conserving Surgery","volume":"15","author":"Shim","year":"2012","journal-title":"J. Breast Cancer"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.radonc.2018.07.024","article-title":"Does deep inspiration breath-hold prolong life? Individual risk estimates of ischaemic heart disease after breast cancer radiotherapy","volume":"131","author":"Simonetto","year":"2019","journal-title":"Radiother. Oncol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.ijrobp.2021.05.110","article-title":"Proton Therapy for Breast Cancer: A Consensus Statement From the Particle Therapy Cooperative Group Breast Cancer Subcommittee","volume":"111","author":"Mutter","year":"2021","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.7150\/ijbs.35460","article-title":"Radiation-induced heart disease: A review of classification, mechanism and prevention","volume":"15","author":"Wang","year":"2019","journal-title":"Int. J. Biol. Sci."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.jacc.2013.04.066","article-title":"Intensification of statin therapy results in a rapid reduction in atherosclerotic inflammation: Results of a multicenter fluorodeoxyglucose-positron emission tomography\/computed tomography feasibility study","volume":"62","author":"Tawakol","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/joic.12245","article-title":"Effect of Statin Therapy on Fibrous Cap Thickness in Coronary Plaques Using Optical Coherence Tomography: A Systematic Review and Meta-Analysis","volume":"28","author":"Zheng","year":"2015","journal-title":"J. Interv. Cardiol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1001\/jama.295.13.jpc60002","article-title":"Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: The ASTEROID trial","volume":"295","author":"Nissen","year":"2006","journal-title":"JAMA"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"8563845","DOI":"10.1155\/2019\/8563845","article-title":"Targeting Early Atherosclerosis: A Focus on Oxidative Stress and Inflammation","volume":"2019","author":"Marchio","year":"2019","journal-title":"Oxid. Med. Cell. Longev."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.radonc.2009.06.020","article-title":"Lovastatin attenuates ionizing radiation-induced normal tissue damage in vivo","volume":"92","author":"Ostrau","year":"2009","journal-title":"Radiother. Oncol."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.3892\/etm.2017.4192","article-title":"Pravastatin reduces radiation-induced damage in normal tissues","volume":"13","author":"Doi","year":"2017","journal-title":"Exp. Ther. Med."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"762","DOI":"10.3892\/ijmm.2017.3047","article-title":"Simvastatin ameliorates ionizing radiation-induced apoptosis in the thymus by activating the AKT\/sirtuin 1 pathway in mice","volume":"40","author":"Yang","year":"2017","journal-title":"Int. J. Mol. Med."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1269\/jrr.09119","article-title":"Protective effect of atorvastatin on radiation-induced vascular endothelial cell injury in vitro","volume":"51","author":"Ran","year":"2010","journal-title":"J. Radiat. Res."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1667\/RR14075.1","article-title":"Atorvastatin Ameliorates Radiation-Induced Cardiac Fibrosis in Rats","volume":"184","author":"Zhang","year":"2015","journal-title":"Radiat. Res."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.radonc.2011.09.019","article-title":"Anti-inflammatory and anti-thrombotic intervention strategies using atorvastatin, clopidogrel and knock-down of CD40L do not modify radiation-induced atherosclerosis in ApoE null mice","volume":"101","author":"Hoving","year":"2011","journal-title":"Radiother. Oncol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1158\/1078-0432.CCR-05-1903","article-title":"Lovastatin protects human endothelial cells from killing by ionizing radiation without impairing induction and repair of DNA double-strand breaks","volume":"12","author":"Nubel","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"e00145","DOI":"10.1002\/prp2.145","article-title":"Simvastatin mitigates increases in risk factors for and the occurrence of cardiac disease following 10 Gy total body irradiation","volume":"3","author":"Lenarczyk","year":"2015","journal-title":"Pharmacol. Res. Perspect."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1667\/RR3302","article-title":"Pravastatin limits endothelial activation after irradiation and decreases the resulting inflammatory and thrombotic responses","volume":"163","author":"Gaugler","year":"2005","journal-title":"Radiat. Res."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1038\/jid.2008.360","article-title":"Pravastatin limits radiation-induced vascular dysfunction in the skin","volume":"129","author":"Holler","year":"2009","journal-title":"J. Invest. Dermatol."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"71","DOI":"10.5853\/jos.2017.01802","article-title":"Incidental Statin Use and the Risk of Stroke or Transient Ischemic Attack after Radiotherapy for Head and Neck Cancer","volume":"20","author":"Addison","year":"2018","journal-title":"J. Stroke"},{"key":"ref_164","doi-asserted-by":"crossref","unstructured":"Hoving, S., Heeneman, S., Gijbels, M.J., te Poele, J.A., Bolla, M., Pol, J.F., Simons, M.Y., Russell, N.S., Daemen, M.J., and Stewart, F.A. (2010). NO-donating aspirin and aspirin partially inhibit age-related atherosclerosis but not radiation-induced atherosclerosis in ApoE null mice. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0012874"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.3332\/ecancer.2021.1258","article-title":"Aspirin and cancer survival: A systematic review and meta-analyses of 118 observational studies of aspirin and 18 cancers","volume":"15","author":"Elwood","year":"2021","journal-title":"Ecancermedicalscience"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"265","DOI":"10.2165\/00003495-200969030-00003","article-title":"Insight into the mode of action of ACE inhibition in coronary artery disease: The ultimate \u2018EUROPA\u2019 story","volume":"69","author":"Ferrari","year":"2009","journal-title":"Drugs"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2165\/00129784-200404060-00004","article-title":"Therapeutic effects of angiotensin (AT1) receptor antagonists: Potential contribution of mechanisms other than AT1 receptor blockade","volume":"4","author":"Schmidt","year":"2004","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.mehy.2008.09.051","article-title":"Does angiotensin II-aldosterone have a role in radiation-induced heart disease?","volume":"72","author":"Wu","year":"2009","journal-title":"Med. Hypotheses"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.radonc.2014.11.017","article-title":"ACE inhibition attenuates radiation-induced cardiopulmonary damage","volume":"114","author":"Ghobadi","year":"2015","journal-title":"Radiother. Oncol."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"20842","DOI":"10.18632\/oncotarget.15356","article-title":"Effect of captopril on radiation-induced TGF-beta1 secretion in EA.Hy926 human umbilical vein endothelial cells","volume":"8","author":"Wei","year":"2017","journal-title":"Oncotarget"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1182\/blood-2003-11-3828","article-title":"Inhibition of angiotensin I-converting enzyme induces radioprotection by preserving murine hematopoietic short-term reconstituting cells","volume":"104","author":"Charrier","year":"2004","journal-title":"Blood"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1016\/j.ijrobp.2009.07.1743","article-title":"Renin-Angiotensin system suppression mitigates experimental radiation pneumonitis","volume":"75","author":"Ghosh","year":"2009","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.2174\/138161207780618777","article-title":"Effect of an angiotensin II receptor blocker and two angiotensin converting enzyme inhibitors on transforming growth factor-beta (TGF-beta) and alpha-actomyosin (alpha SMA), important mediators of radiation-induced pneumopathy and lung fibrosis","volume":"13","author":"Molteni","year":"2007","journal-title":"Curr. Pharm. Des."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/j.jacc.2013.08.726","article-title":"Colchicine and the heart: Pushing the envelope","volume":"62","author":"Deftereos","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jacc.2012.10.027","article-title":"Low-dose colchicine for secondary prevention of cardiovascular disease","volume":"61","author":"Nidorf","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"e021198","DOI":"10.1161\/JAHA.121.021198","article-title":"Colchicine in Patients With Coronary Artery Disease: A Systematic Review and Meta-Analysis of Randomized Trials","volume":"10","author":"Kofler","year":"2021","journal-title":"J. Am. Heart Assoc."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.mehy.2017.12.021","article-title":"Prophylactic use of colchicine in preventing radiation induced coronary artery disease","volume":"111","author":"Lafferty","year":"2018","journal-title":"Med. Hypotheses"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.clinthera.2018.11.016","article-title":"Why Colchicine Should Be Considered for Secondary Prevention of Atherosclerosis: An Overview","volume":"41","author":"Nidorf","year":"2019","journal-title":"Clin. Ther."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41568-020-00308-y","article-title":"The rediscovery of platinum-based cancer therapy","volume":"21","author":"Rottenberg","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"a006577","DOI":"10.1101\/cshperspect.a006577","article-title":"Anti-VEGF therapies in the clinic","volume":"2","author":"Meadows","year":"2012","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_182","unstructured":"Kufe, D.W., Pollock, R.E., Weichselbaum, R.R., Bast, J.R.C., Gansler, T.S., Holland, J.F., and Frei, I.E. (2003). Cardiac complications of cancer treatment. Cancer Medicine, BC Decker Inc."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"4571","DOI":"10.1038\/s41467-019-12594-8","article-title":"5-Fluorouracil treatment induces characteristic T>G mutations in human cancer","volume":"10","author":"Christensen","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_184","doi-asserted-by":"crossref","unstructured":"Lukasiewicz, S., Czeczelewski, M., Forma, A., Baj, J., Sitarz, R., and Stanislawek, A. (2021). Breast Cancer-Epidemiology, Risk Factors, Classification, Prognostic Markers, and Current Treatment Strategies-An Updated Review. Cancers, 13.","DOI":"10.3390\/cancers13174287"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3389\/fcvm.2020.00026","article-title":"Cardiotoxicity of Anthracyclines","volume":"7","author":"Cardinale","year":"2020","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1161\/CIRCULATIONAHA.114.013777","article-title":"Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy","volume":"131","author":"Cardinale","year":"2015","journal-title":"Circulation"},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.bbagen.2005.10.012","article-title":"The anti-cancer drug, doxorubicin, causes oxidant stress-induced endothelial dysfunction","volume":"1760","author":"Wolf","year":"2006","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.tiv.2014.12.009","article-title":"Comparative endothelial profiling of doxorubicin and daunorubicin in cultured endothelial cells","volume":"29","author":"Wojcik","year":"2015","journal-title":"Toxicol. In Vitro"},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1038\/sj.bjp.0703959","article-title":"Chronic vascular toxicity of doxorubicin in an organ-cultured artery","volume":"132","author":"Murata","year":"2001","journal-title":"Br. J. Pharmacol."},{"key":"ref_190","doi-asserted-by":"crossref","unstructured":"Eckman, D.M., Stacey, R.B., Rowe, R., D\u2019Agostino, R., Kock, N.D., Sane, D.C., Torti, F.M., Yeboah, J., Workman, S., and Lane, K.S. (2013). Weekly doxorubicin increases coronary arteriolar wall and adventitial thickness. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0057554"},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1093\/cvr\/cvab053","article-title":"Coronary microcirculation damage in anthracycline cardiotoxicity","volume":"118","author":"Lobo","year":"2022","journal-title":"Cardiovasc. Res."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1007\/s12350-018-1458-6","article-title":"Rubidium-82 positron emission tomography for detection of acute doxorubicin-induced cardiac effects in lymphoma patients","volume":"27","author":"Laursen","year":"2020","journal-title":"J. Nucl. Cardiol."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"251","DOI":"10.7861\/clinmed.2021-0600","article-title":"Radiation-induced coronary artery disease: A difficult clinical conundrum","volume":"22","author":"Kirresh","year":"2022","journal-title":"Clin. Med."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1093\/eurheartj\/ehab674","article-title":"Defining cardiovascular toxicities of cancer therapies: An International Cardio-Oncology Society (IC-OS) consensus statement","volume":"43","author":"Herrmann","year":"2022","journal-title":"Eur. Heart J."}],"container-title":["Life"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-1729\/12\/7\/1034\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:48:33Z","timestamp":1760140113000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-1729\/12\/7\/1034"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,12]]},"references-count":194,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,7]]}},"alternative-id":["life12071034"],"URL":"https:\/\/doi.org\/10.3390\/life12071034","relation":{},"ISSN":["2075-1729"],"issn-type":[{"value":"2075-1729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,12]]}}}